NCT05683418 - A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors | Biotech Hunter

Enrollment

241

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Squamous Cell Carcinoma of Head and NeckEndometrial CancerHR+/HER2-negative Breast CancerBladder Cancer

Interventions

DRUG

TOS-358

Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor

Trial Locations (18)

19106

RECRUITING

University of Pennsylvania, Philadelphia

22031

RECRUITING

Virginia Cancer Specialists, PC, Fairfax

28040

RECRUITING

Hospital Clinico San Carlos, Madrid

28050

RECRUITING

START MADRID Hospital Universitario Fundacion Jimenez Diaz - EDOS, Madrid

RECRUITING

START MADRID Hospital Universitario HM Sanchinarro - CIOCC, Madrid

28223

RECRUITING

NEXT Oncology - Hospital Quironsalud Madrid - PPDS, Pozuelo de Alarcón

31008

RECRUITING

Clinica Universidad de Navarra, Pamplona

37232

RECRUITING

Vanderbilt-Ingram Cancer Center, Nashville

46010

RECRUITING

Hospital Clinico Universitario de Valencia, Valencia

60611

RECRUITING

Northwestern Memorial Hospital, Chicago

73104

RECRUITING

Stephenson Cancer Center, Oklahoma City

90033

RECRUITING

University of Southern California, Norris Comprehensive Cancer Center, Los Angeles

02114

RECRUITING

Massachusetts General Hospital Cancer Center, Boston

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

08023

RECRUITING

NEXT Oncology - Hospital Quironsalud Barcelona - PPDS, Barcelona

RECRUITING

START Barcelona HM Nou Delfos, Barcelona

08035

RECRUITING

Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON, Barcelona